Blockade of G Protein-Coupled Receptors and the Dopamine Transporter by a Transmembrane Domain Peptide: Novel Strategy for Functional Inhibition of Membrane Proteins in Vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 307, Issue 2, 2003, Pages 481-489

  George, Susan R ^a,b,c   Ng, Gordon Y K ^b,d   Lee, Samuel P ^a   Fan, Theresa ^c   Varghese, George ^a   Wang, Chen ^a   Deber, Charles M ^a   Seeman, Philip ^a,b   O'Dowd, Brian F ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; COCAINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; G PROTEIN COUPLED RECEPTOR; MEMBRANE PROTEIN; PEPTIDE DERIVATIVE; PROTEIN INHIBITOR; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ALPHA HELIX; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR EFFECT; CAUDATE NUCLEUS; CIRCLING BEHAVIOR; CIRCULAR DICHROISM; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEART RATE; HYDROPHOBICITY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIGAND BINDING; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RAT; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; URINE VOLUME;

ANIMALS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 0142241304     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.053843     Document Type: Article

References (39)

1. Baldwin JM (1993) The probable arrangement of the helices in G protein-coupled receptors. EMBO (Eur Mol Biol Organ) J 12:1693-1703.
2. Baldwin JM, Schertler GF, and Unger VM (1997) An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J Mol Biol 272:144-164.
3. Ballesteros JA, Shi L, and Javitch JA (2001) Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol Pharmacol 60:1-19.
4. Bickel U, Yoshikawa T, and Pardridge WM (2001) Delivery ofpeptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 46:247-279.
5. Chen N and Reith MEA (2000) Structure and function of the dopamine transporter. Eur J Pharmacol 405:329-339.
6. Costall B, Kelly ME, and Naylor RJ (1983) The production of asymmetry and circling behaviour following unilateral, intrastriatal administration ofneuroleptic agents: a comparison of abilities to antagonise striatal function. Eur J Pharmacol 96:79-86.
7. da Silva Tatley F, Aldwell FE, Dunbier AK, and Guilford PJ (2003) N-Terminal E-cadherin peptides act as decoy receptors for Listeria monocytogenes. Infect Immun 71:1580-1583.
8. Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018.
9. George SR, Lee SP, Varghese G, Zeman PR, Seeman P, Ng GYK, and O'Dowd BF (1998) A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization. J Biol Chem 273:30244-30248.
10. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, and Bouvier M (1996) A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271:16384-16392.
11. Kieber-Emmons T, Murali R, and Greene MI (1997) Therapeutic peptides and peptidomimetics. Curr Opin Biotechnol 8:435-441.
12. Kiesel LA, Rody A, Greb RR, and Szilagyi A (2002) Clinical use of GnRH analogues. Clin Endocrinol 56:677-687.
13. Lee SP, O'Dowd BF, Ng GY, Varghese G, Akil H, Mansour A, Nguyen T, and George SR (2000) Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell. Mol Pharmacol 58:120-128.
14. Liu LP and Deber CM (1998) Guidelines for membrane protein engineering derived from de novo designed model peptides. Biopolymers 47:41-62.
15. MacKenzie KR, Prestegard JH, and Engelman DM (1997) A transmembrane helix dimer: structure and implications. Science (Wash DC) 276:131-133.
16. Melnyk RA, Partridge AW, and Deber CM (2001) Retention of native-like oligomerization states in transmembrane segment peptides: application to the Escherichia coli aspartate receptor. Biochemistry 40:11106-11113.
17. Myers JK, Pace CN, and Scholtz JM (1997a) A direct comparison of helix propensity in proteins and peptides. Proc Natl Acad Sci USA 94:2833-2837.
18. Myers JK, Pace CN, and Scholtz JM (1997b) Helix propensities are identical in proteins and peptides. Biochemistry 36:10923-10929.
19. Nelson N (1998) The family of Na+/Cl neurotransmitter transporters. J Neurochem 71:1785-1803.
20. Ng GY, O'Dowd BF, Caron M, Dennis M, Brann MR, and George SR (1994) Phosphorylation and palmitoylation of the human D2L dopamine receptor in Sf9 cells. J Neurochem 63:1589-1595.
21. Oesterhelt F, Oesterhelt D, Pfeiffer M, Engel A, Gaub HE, and Muller DJ (2000) Unfolding pathways of individual bacteriorhodopsins. Science (Wash DC) 288:143-146.
22. Okamoto T, Murayama Y, Hayashi Y, Inagaki M, Ogata E, and Nishimoto I (1991) Identification of a Gs activator region of the beta 2-adrenergic receptor that is autoregulated via protein kinase A-dependent phosphorylation. Cell 67:723-730.
23. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science (Wash DC) 289:739-745.
24. Pan G, Ni J, Wei YF, Yu G, Gentz R, and Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (Wash DC) 277:815-818.
25. Paxinos G and Watson C (1982) The Rat Brain in Stereotaxic Coordinates, Academic Press, New York.
26. Perlman JH, Colson AO, Wang W, Bence K, Osman R, and Gershengorn MC (1997) Interactions between conserved residues in transmembrane helices 1, 2 and 7 of the thyrotropin-releasing hormone receptor. J Biol Chem 272:11937-11942.
27. Scheer A, Fanelli F, Costa T, De Benedetti PG, and Cotecchia S (1996) Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. EMBO (Eur Mol Biol Organ) J 15:3566-3578.
28. Sealfon SC, Chi L, Ebersole BJ, Rodic V, Zhang D, Ballesteros JA, and Weinstein H (1995) Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor. J Biol Chem 270:16683-16688.
29. Shai Y (1995) Molecular recognition between membrane-spanning polypeptides. Trends Biochem Sci 20:460-464.
30. Sheikh SP, Vilardarga JP, Baranski TJ, Lichtarge O, Iiri T, Meng EC, Nissenson RA, and Bourne HR (1999) Similar structures and shared switch mechanisms of the beta2-adrenoceptor and the parathyroid hormone receptor. Zn(II) bridges between helices III and VI block activation. J Biol Chem 274:17033-17041.
31. Strader CD, Fong TM, Tota MR, Underwood D, and Dixon RA (1994) Structure and function of G protein-coupled receptors. Annu Rev Biochem 63:101-132.
32. Suryanarayana S, von Zastrow M, and Kobilka BK (1992) Identification of intramolecular interactions in adrenergic receptors. J Biol Chem 267:21991-21994.
33. Tanaka T, Kohno T, Kinoshita S, Mukai H, Itoh H, Ohya M, Miyazawa T, Higashijima T, and Wakamatsu K (1998) Alpha helix content of G protein alpha subunit is decreased upon activation by receptor mimetics. J Biol Chem 273:3247-3252.
34. Tarasova NI, Rice WG, and Michejda CJ (1999) Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions. J Biol Chem 274:34911-34915.
35. Therien AG and Deber CM (2002) Oligomerization of a peptide derived from the transmembrane region of the sodium pump gamma subunit: effect of the pathological mutation G41R. J Mol Biol 322:583-590.
36. Torchilin VP and Lukyanov AN (2003) Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 8:259-266.
37. Torres GE, Carneiro A, Seamans K, Fiorentini C, Sweeney A, Yao W-D, and Caron MG (2003) Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol Chem 278:2731-2739.
38. Voss T, Wallner E, Czernilofsky AP, and Freissmuth M (1993) Amphipathic alpha-helical structure does not predict the ability of receptor-derived synthetic peptides to interact with guanine nucleotide-binding regulatory proteins. J Biol Chem 268:4637-4642.
39. Wang C and Deber CM (2000) Peptide mimics of the M13 coat protein transmembrane segment. Retention of helix-helix interaction motifs. J Biol Chem 275:16155-16159.